The Role of F-18- FDG PET and PET/CT in Lung Cancer

Positron emission tomography (PET) has the unique ability to image bodily functions, such as blood flow, oxygen use, and glucose metabolism. PET imaging in combination with computerized tomography (CT) offers a high sensitivity scan for metabolic activity with precise anatomical localization. PET/CT with the glucose analog 18F-fluorodeoxyglucose (FDG) has become an essential tool for the work-up of patients with cancer for clinical practice. F-18-FDG PET/CT provides valuable information about differential diagnosis, staging and therapy response of oncologic disease. Lung cancer remains the most common cause of death from malignant disease in the world both in women and in men. In this article, the role of F-18-FDG PET and F-18-FDG PET/CT in lung cancers have been reviewed [Archives Medical Review Journal 2013; 22(4.000): 470-485

The value of F-18-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up

WOS: 000272915000010PubMed ID: 19952921Background The management of the patients with carcinoma of an unknown primary represents a difficult challenge in oncology. F-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has provided new insights in the diagnosis, staging, and follow-up of oncological patients. Aim This study aimed to investigate the value of FDG PET/CT in clarifying the primary site in our patients with histologically proven tumor metastasis (HPM) or with a high clinical suspicion of malignancy, and the clinical impact of this technique on the management of these patients. Methods In total 94 patients from two centers underwent FDG PET/CT imaging; 78 patients with HPIVI and 16 patients with a clinical suspicion of malignancy. The histology and/or follow-up data were used as the gold standard. Hypermetabolic findings at the site of the pathological CT changes or at physiological FDG uptake sites were the criteria for malignancy. PET/CT findings were analyzed for the identification of the primary tumor site, for the relationship with survival, and also for the effect in chemotherapy monitoring. Results Primary malignancy was discovered in 53 of 90 patients (59%) histologically and 37 (41%) patients' primary tumor sites were not found during the study period. Amongst 90 patients, five (6%) were normal on FDG PET/CT. Of 85 patients (94%) with pathological findings on FDG PET/CT, 27 patients (32%) had solitary and 58 (68%) patients had multiple organs affected. Regarding the whole study population, a sensitivity of 74% and a specificity of 78% were calculated for FDG PET/CT imaging. Regarding the patients with HPM, the sensitivity and specificity values were 84 and 81%, respectively. The mean survival time of the patients with disseminated disease was significantly shorter than those of the patients with single or no lesion (13.44 +/- 1.61, 20.98 +/- 2.0 and 26.67 +/- 2.73 months, respectively, P = 0.014). In seven of eight patients, follow-up FDG PET/CT scans effectively monitored the patients' therapies. Conclusion Whole-body FDG PET/CT has to be considered a useful method, especially in an early phase of the diagnostic workup of patients with carcinoma of an unknown primary syndrome, to optimize the management. Nucl Med Commun 31:59-66 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins